XLO Xilio Therapeutics Inc.

FDA Catalyst Company
2.47
+0.07  (+3%)
Previous Close 2.4
Open 2.54
52 Week Low 2.36
52 Week High 27.95
Market Cap $67,854,869
Shares 27,471,607
Float 21,870,479
Enterprise Value $-90,625,144
Volume 118,349
Av. Daily Volume 40,947
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/10/2022
Raymond James Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/16/2021
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/16/2021
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/16/2021

Latest News

  1. WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 2:30 p.m. ET.

    A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.

    About Xilio Therapeutics
    Xilio Therapeutics is a clinical-stage biotechnology company…

    View Full Article
  2. WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Stacey Davis has been appointed as chief business officer to further the company's corporate and business development strategy that will be central to its next stage of growth.

    "As an accomplished life science leader, Stacey brings significant strategic business experience building successful portfolios in oncology and immunology with an in-depth knowledge of the real-world patient and physician experience," said René Russo, Pharm.D., president and chief executive officer of Xilio. "Her broad operational and business development…

    View Full Article
  3. Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022

    On track with plans to submit IND for XTX301, a tumor-selective IL-12, in second half of 2022

    Strong financial position with $177 million in cash and cash equivalents as of March 31, 2022, with cash runway anticipated into first half of 2024

    WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced pipeline and business highlights and reported financial results for the first quarter ended March 31, 2022.

    "Leveraging our…

    View Full Article
  4. WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 8:00 a.m. ET.

    A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.

    About Xilio Therapeutics
    Xilio Therapeutics is a clinical-stage biotechnology company focused…

    View Full Article
  5. Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022

    On Track with Plans to Submit IND for XTX301 in Second Half of 2022

    Continue to Anticipate Cash Runway into 2024 with $198.1 Million in Cash and Cash Equivalents at Year-End 2021

    WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced pipeline and business progress and reported financial results for the fourth quarter and full year ended December 31, 2021.

    "Xilio made significant pipeline and business progress in 2021, becoming a clinical-stage organization and transitioning to a publicly…

    View Full Article
View All Xilio Therapeutics Inc. News